Sign in Join free

Research area · 9 entries

GH axis & secretagogues

GHRH analogs, ghrelin mimetics, and GH-releasing peptides in pituitary-axis research.

Filter by research area

9 entries

Compound	Class	Research area	Summary	Roundup
IpamorelinGrowth hormone secretagogueGhrelin receptor (GHS-R) agonist · GH axis & secretagogues	Ghrelin receptor (GHS-R) agonist	GH axis & secretagogues	Ipamorelin is a selective growth hormone secretagogue studied for relatively narrow hormonal release profiles compared with first-generation GHRPs. It is frequently paired in research discussions with GHRH analogs such as CJC-1295.	Yes
CJC-1295 (with DAC)Modified GRF(1-29) with DACLong-acting GHRH analog · GH axis & secretagogues	Long-acting GHRH analog	GH axis & secretagogues	CJC-1295 with DAC is a GHRH analog modified for extended exposure via albumin-binding chemistry. Pharmacokinetics differ substantially from the no-DAC form — they are separate research materials, not interchangeable vials.	Yes
CJC-1295 (no DAC)Mod GRF(1-29)Short-acting GHRH analog · GH axis & secretagogues	Short-acting GHRH analog	GH axis & secretagogues	The no-DAC form of CJC-1295 is a shorter-acting GHRH analog than the DAC-modified variant. Research discussions often pair it with ipamorelin or GHRP-class peptides — combination data remain predominantly preclinical.	Yes
GHRP-2PralmorelinGhrelin mimetic hexapeptide · GH axis & secretagogues	Ghrelin mimetic hexapeptide	GH axis & secretagogues	GHRP-2 is a first-generation growth hormone releasing peptide characterized in 1990s secretagogue research. It remains a reference compound in comparative GH-axis pharmacology literature.	Yes
GHRP-6Growth hormone releasing peptide-6Ghrelin mimetic hexapeptide · GH axis & secretagogues	Ghrelin mimetic hexapeptide	GH axis & secretagogues	GHRP-6 was among the first synthetic GHRPs characterized in ghrelin receptor research. Rodent literature documents appetite-stimulating effects alongside GH release — distinguishing it from more selective later compounds.	Yes
HexarelinExamorelinGhrelin mimetic hexapeptide · GH axis & secretagogues	Ghrelin mimetic hexapeptide	GH axis & secretagogues	Hexarelin is a potent hexapeptide ghrelin mimetic cited in GH-axis research and, separately, in rodent cardiac ischemia-reperfusion models. Cardioprotective preclinical findings do not establish clinical cardiac benefit.	Yes
IGF-1 LR3Long R3-IGF-1IGFBP-resistant IGF-1 analog · GH axis & secretagogues	IGFBP-resistant IGF-1 analog	GH axis & secretagogues	IGF-1 LR3 is an engineered IGF-1 analog with an Arg3 substitution and N-terminal extension that evades IGFBP sequestration. Widely used in cell culture and rodent research; no FDA approval and WADA-prohibited.	Yes
SermorelinGHRH(1-29)GHRH(1-29) analog · GH axis & secretagogues	GHRH(1-29) analog	GH axis & secretagogues	Sermorelin is the classical GHRH(1-29) analog with FDA approval history for pediatric GH deficiency (Geref, withdrawn commercially). Short half-life distinguishes it from tesamorelin and DAC-modified CJC-1295.	Yes
TesamorelinTH9507N-terminally modified GHRH(1-44) analog · GH axis & secretagogues	N-terminally modified GHRH(1-44) analog	GH axis & secretagogues	Tesamorelin is an FDA-approved GHRH analog studied in phase 3 trials for HIV-associated lipodystrophy with excess visceral adipose tissue. Catalog material is a distinct RUO supply chain from pharmaceutical Egrifta.	Yes

Community content — not medical advice. Research use only; nothing here is instruction for human use.